Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Curr Opin Pediatr ; 36(2): 204-210, 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-38001558

ABSTRACT

PURPOSE OF REVIEW: Hyperkalemia is a potentially fatal electrolyte abnormality with no standardized management. The purpose of this review is to provide the knowledge needed for timely and effective management of hyperkalemia in children. It describes the utility of existing and novel therapies. RECENT FINDINGS: Two newer oral potassium binding agents, patiromer sorbitex calcium and sodium zirconium cyclosilicate, have been FDA-approved for the management of hyperkalemia in adults. These newer agents offer hope for improved management, even though their use in pediatric patients requires further exploration. SUMMARY: This review highlights the causes and life-threatening effects of hyperkalemia and provides a comprehensive overview of the management of hyperkalemia in both acute and chronic settings along with upcoming treatment strategies.


Subject(s)
Hyperkalemia , Humans , Child , Hyperkalemia/diagnosis , Hyperkalemia/drug therapy , Hyperkalemia/etiology , Potassium/therapeutic use , Potassium/pharmacology , Renin-Angiotensin System
3.
Pediatrics ; 139(5)2017 May.
Article in English | MEDLINE | ID: mdl-28557733

ABSTRACT

A 9-day-old infant girl presented with diarrhea and weight loss of 19% since birth. She was born via spontaneous vaginal delivery at 39 weeks' gestation to a mother positive for group B Streptococcus who received adequate intrapartum prophylaxis. The infant was formula-fed every 2 to 3 hours with no reported issues with feeding or swallowing. The infant had nonmucoid watery stools ∼5 to 15 times per day. Her family history was significant for hypertrophic cardiomyopathy in several of her family members. Her initial vital signs and physical examination were normal. Laboratory data on hospital admission showed a normal complete blood cell count, but her chemistry analysis revealed significant hypernatremia, hyperkalemia, metabolic acidosis, and acute kidney injury. Her hypernatremia was resistant to fluid management. In this article, we discuss the infant's hospital course, our clinical thought process, and how we arrived at our final diagnosis.


Subject(s)
Carbohydrate Metabolism, Inborn Errors/diagnosis , Diarrhea/etiology , Malabsorption Syndromes/diagnosis , Sodium-Glucose Transporter 1/genetics , Weight Loss , Carbohydrate Metabolism, Inborn Errors/therapy , Diagnosis, Differential , Female , Humans , Infant, Newborn , Malabsorption Syndromes/therapy
4.
Pediatr Transplant ; 20(3): 378-87, 2016 May.
Article in English | MEDLINE | ID: mdl-26880121

ABSTRACT

The chronic kidney disease-mineral bone disorder (CKD-MBD) produces fibroblast growth factor-23 (FGF-23) and related circulating pathogenic factors that are strongly associated with vascular injury and declining kidney function in native CKD. Similarly, chronic renal allograft injury (CRAI) is characterized by vascular injury and declining allograft function in transplant CKD. We hypothesized that circulating CKD-MBD factors could serve as non-invasive biomarkers of CRAI. We conducted a cross-sectional, multicenter case-control study. Cases (n = 31) had transplant function >20 mL/min/1.73 m(2) and biopsy-proven CRAI. Controls (n = 31) had transplant function >90 mL/min/1.73 m(2) and/or a biopsy with no detectable abnormality in the previous six months. We measured plasma CKD-MBD factors at a single time point using ELISA. Median (range) FGF23 levels were over twofold higher in CRAI vs. controls [106 (10-475) pg/mL vs. 45 (8-91) pg/mL; p < 0.001]. FGF23 levels were inversely correlated with transplant function (r(2) = -0.617, p < 0.001). Higher FGF23 levels were associated with increased odds of biopsy-proven CRAI after adjusting for transplant function, clinical, and demographic factors [OR (95% CI) 1.43 (1.23, 1.67)]. Relationships between additional CKD-MBD factors and CRAI were attenuated in multivariable models. Higher FGF23 levels were independently associated with biopsy-proven CRAI in children.


Subject(s)
Fibroblast Growth Factors/blood , Kidney Failure, Chronic/surgery , Kidney Transplantation/adverse effects , Kidney Transplantation/methods , Nephrology/methods , Adolescent , Allografts , Biomarkers/blood , Biopsy , Case-Control Studies , Cross-Sectional Studies , Enzyme-Linked Immunosorbent Assay , Female , Fibroblast Growth Factor-23 , Glomerular Filtration Rate , Humans , Male , Multivariate Analysis , Regression Analysis , Sensitivity and Specificity , Treatment Outcome , Young Adult
5.
Pediatr Transplant ; 20(1): 59-67, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26585354

ABSTRACT

Several centers have examined the implementation of immunosuppression protocols that minimize steroid exposure. This study retrospectively examined cardiovascular risk factors in 70 pediatric renal transplant recipients on steroid avoidance-based immunosuppression over three yr compared to matched pediatric patients maintained on chronic corticosteroids. Although higher rates of acute rejection were noted in the steroid-avoidant group (22% vs. 16%, p = 0.034), graft function was similar (67 + 10 mL/min/1.73 m(2) vs. 72 + 12 mL/min/1.73 m(2)) (p = 0.053). The steroid-avoidant group demonstrated improved growth (height z-score -0.41 + 5.9 vs. -1.1 + 0.041) with a decrease in the prevalence of obesity (24% vs. 34%, p = 0.021). Indexed systolic blood pressures were lower beginning at six months post-transplant in the steroid-avoidant group (1.21 + 0.15 vs. 1.51 + 0.22, p = 0.020). Indexed diastolic blood pressures were lower beginning at 12 months post-transplant (0.91 + 0.11 vs. 1.12 + 0.18, p = 0.037). Differences in total serum cholesterol values and serum glucose values were not statistically significant. Beginning at 12 months, a statistically significant decrease in left ventricular mass index (39.2 + 11.3 vs. 49.4 + 14.5, p = 0.014) was noted in patients on steroid-avoidant immunosuppression, which corresponded to a significant decrease in the prevalence of left ventricular hypertrophy in these patients by two yr post-transplant (35% vs. 48%, p = 0.012). Systolic blood pressure and BMI were independent predictors of left ventricular hypertrophy.


Subject(s)
Cardiovascular Diseases/complications , Immunosuppressive Agents/therapeutic use , Kidney Transplantation , Renal Insufficiency/surgery , Steroids/therapeutic use , Adolescent , Blood Glucose/analysis , Body Mass Index , Cardiovascular Diseases/prevention & control , Child , Child, Preschool , Cholesterol/blood , Diastole/drug effects , Female , Graft Rejection , Humans , Immunosuppression Therapy , Male , Midwestern United States , Nephrology , Obesity/complications , Pediatrics , Postoperative Period , Retrospective Studies , Risk Factors , Software , Systole/drug effects , Treatment Outcome , Ventricular Function, Left
6.
J Am Soc Nephrol ; 26(7): 1701-10, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25349203

ABSTRACT

Steroid-sensitive nephrotic syndrome (SSNS) accounts for >80% of cases of nephrotic syndrome in childhood. However, the etiology and pathogenesis of SSNS remain obscure. Hypothesizing that coding variation may underlie SSNS risk, we conducted an exome array association study of SSNS. We enrolled a discovery set of 363 persons (214 South Asian children with SSNS and 149 controls) and genotyped them using the Illumina HumanExome Beadchip. Four common single nucleotide polymorphisms (SNPs) in HLA-DQA1 and HLA-DQB1 (rs1129740, rs9273349, rs1071630, and rs1140343) were significantly associated with SSNS at or near the Bonferroni-adjusted P value for the number of single variants that were tested (odds ratio, 2.11; 95% confidence interval, 1.56 to 2.86; P=1.68×10(-6) (Fisher exact test). Two of these SNPs-the missense variants C34Y (rs1129740) and F41S (rs1071630) in HLA-DQA1-were replicated in an independent cohort of children of white European ancestry with SSNS (100 cases and ≤589 controls; P=1.42×10(-17)). In the rare variant gene set-based analysis, the best signal was found in PLCG2 (P=7.825×10(-5)). In conclusion, this exome array study identified HLA-DQA1 and PLCG2 missense coding variants as candidate loci for SSNS. The finding of a MHC class II locus underlying SSNS risk suggests a major role for immune response in the pathogenesis of SSNS.


Subject(s)
Genetic Predisposition to Disease/epidemiology , HLA-DQ alpha-Chains/genetics , Nephrotic Syndrome/epidemiology , Nephrotic Syndrome/genetics , Phospholipase C gamma/genetics , Steroids/therapeutic use , Age Distribution , Age of Onset , Alleles , Case-Control Studies , Child , Child, Preschool , Cohort Studies , Female , Genotype , Humans , Incidence , Male , Mutation, Missense , Nephrotic Syndrome/drug therapy , Sex Distribution , Sri Lanka/epidemiology
7.
Prog Transplant ; 23(1): 78-83, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23448826

ABSTRACT

OBJECTIVE: As kidney transplant is the preferred mode of management of advanced kidney disease and economic trends for kidney transplant procedures are not well known, data were analyzed to assess these trends. DATA SOURCE: Annual data for 1998 to 2008 from the Nationwide Inpatient Sample, Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality were used to analyze characteristics of patients discharged from hospitals in the United States with kidney transplant as the primary procedure. DATA SYNTHESIS/RESULTS: The population more than 65 years old had the most significant increase in hospitalizations for kidney transplant procedures (P< .01). The mean length of stay decreased by 2.8 days over the period studied (P= .02). Mean hospital charge increased despite a decrease in length of stay resulting in a 225% increase in charge per day of hospitalization, from $6907 in 1998 to $22 484 in 2008. The national aggregate hospital charges for kidney transplant procedures rose from $0.9 billion in 1998 to $3.1 billion in 2008. Kidney transplant was overall ranked sixth by mean cost per hospitalization and ranked seventh by mean charge per hospitalization among the Clinical Classification Software's Services and Procedures in this database in 2008. CONCLUSION: Despite shorter hospital stays, the economic burden of kidney transplants increased from 1998 to 2008.


Subject(s)
Health Care Costs/trends , Kidney Transplantation/economics , Adolescent , Adult , Age Distribution , Aged , Cross-Sectional Studies , Hospital Charges , Humans , Kidney Transplantation/statistics & numerical data , Length of Stay , Middle Aged , Retrospective Studies , United States
8.
Adv Chronic Kidney Dis ; 18(5): 324-31, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21896373

ABSTRACT

Poor growth is a common sequela of CKD in childhood. It not only affects the psychosocial development of a child but also has significant effects even in the adult life. The multifactorial etiology and severe consequences of growth failure in CKD warrant evaluation of all the modifiable and nonmodifiable causes. Treatment strategies must be directed toward the specific factors for each child with CKD. Among the various metabolic, nutritional, and hormonal disturbances complicating CKD, disordered growth hormone (GH) and insulin-like growth factor-1 axis are important contributors toward poor growth in children with CKD. CKD is recognized as a state of GH resistance rather than GH deficiency, with multiple mechanisms contributing to this GH resistance. Recombinant GH (rGH) therapy can be used in this population to accelerate growth velocity. Although its use has been shown to be effective and safe in children with CKD, there continues to be some uncertainty and reluctance among practitioners and families regarding its usage, thereby resulting in a surprisingly low use in children with CKD. This review focuses on the pathogenesis of growth failure, its effect, and management strategies in children with CKD.


Subject(s)
Child Development , Growth Disorders/etiology , Kidney Diseases/complications , Kidney Diseases/physiopathology , Adult , Child , Child, Preschool , Chronic Disease , Growth/drug effects , Growth/physiology , Growth Disorders/drug therapy , Human Growth Hormone/physiology , Human Growth Hormone/therapeutic use , Humans , Insulin-Like Growth Factor I/physiology
9.
Clin Transplant ; 25(5): E469-74, 2011.
Article in English | MEDLINE | ID: mdl-21554398

ABSTRACT

Chronic kidney disease can severely impair linear growth in children. For many children, growth improves after renal transplantation, but for some, growth velocity remains low and for others, catch-up growth is insufficient to compensate for the deficit imparted by renal disease in the preceding years. Inadequate final adult height after renal transplant is multifactorial and can adversely affect the quality of life (QOL), psychosocial development and long term prospects for these children as they grow into adulthood. Growth failure after renal transplant requires thorough evaluation and its management in renal transplant recipients can involve improved nutritional intake, correction of metabolic acidosis, treatment of secondary hyperparathyroidism, steroid-sparing immunosuppression and/or use of recombinant human growth hormone (rGH). Treatment with rGH after renal transplant has been evaluated by a limited number of clinical trials suggesting efficacy and safety for this treatment strategy. Several important clinical questions regarding rGH use in children post-renal transplant remain unanswered.


Subject(s)
Growth Disorders/drug therapy , Growth Disorders/etiology , Human Growth Hormone/therapeutic use , Kidney Failure, Chronic/complications , Kidney Transplantation/adverse effects , Postoperative Complications , Child , Humans , Kidney Failure, Chronic/surgery
10.
Nephrol Dial Transplant ; 26(8): 2503-8, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21220753

ABSTRACT

BACKGROUND: Hyperkalemia, due to its effect on cardiac conductivity, is a potentially life-threatening electrolyte abnormality. Multiple therapeutic agents may be used alone or in combination for its prompt management. METHODS: We report on the safety and efficacy of continuous infusion of a solution containing fixed concentrations of calcium gluconate, insulin, dextrose and sodium acetate (HyperK-Cocktail) for the treatment of hyperkalemia. This solution is prepared at our institution and is infused parenterally until the plasma potassium level stabilizes. Twenty-one consecutive hyperkalemic patients managed with HyperK-Cocktail on 23 occasions are reported. RESULTS: None of the subjects had intravenous extravasation injuries, hypernatremia, hypocalcemia, hypercalcemia or alkalosis during HyperK-Cocktail infusion. Transient hyperglycemia developed in nine subjects and hypoglycemia in one subject. The decrease in serum potassium was similar in the initial hour when compared to prior studies using a beta-agonist and/or insulin and glucose; a larger decrease was present from 2 to 8 h with the HyperK-Cocktail. The plasma potassium decreased by a mean of 1.0, 1.7, 2.1 and 2.1 mmol/L at 1, 2, 4 and 8 h, respectively. The mean serum potassium at hours 1-8 was significantly lower than the initial level. CONCLUSION: The results of our study demonstrated that HyperK-Cocktail is a safe and effective combination therapy for children with hyperkalemia.


Subject(s)
Calcium Gluconate/administration & dosage , Glucose/administration & dosage , Hyperkalemia/drug therapy , Insulin/administration & dosage , Sodium Acetate/administration & dosage , Adolescent , Child , Child, Preschool , Disease Management , Female , Humans , Infant , Infant, Newborn , Infusions, Intravenous , Male , Prognosis , Retrospective Studies , Solutions
SELECTION OF CITATIONS
SEARCH DETAIL
...